Introduction
Lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), is the major cause of cancer death in the United States (Minna et al., 1989) . Increasing evidence suggests that lung cancer is the result of a series of molecular changes, including activation or overexpression of oncogenes, and loss or mutation of tumor suppressor genes (Herzog et al., 1997) . Several genetic changes including hypermethylation of p16, p53 mutation, and deletion of 3p, 9p and 17p, were frequently detected in lung hyperplasia and dysplasia (Bennett et al., 1993; Kishimoto et al., 1995; Merlo et al., 1995; Palmisano et al., 1998; Sozzi et al., 1992) . Activation of the K-ras gene is frequently observed in lung adenocarcinomas in smokers (Rodenhuis et al., 1988) . Inactivation of p16 by hypermethylation and homozygous deletion was detected in the majority of non-small cell lung carcinomas (Merlo et al., 1995; Palmisano et al., 1998) . Further, p53 mutations and Rb inactivation were frequently seen in invasive carcinomas (Chiba et al., 1990; Xu et al., 1991) . Finally, loss of heterozygosity (LOH) of ®ve loci (3p, 5q, 9p, 13q, and 17p) was frequently observed in carcinomas in situ of the lung (Gazdar et al., 1994) . Deletion of 18q and 22q was seen only in invasive carcinomas suggesting that the genes in these two loci may be responsible for malignant progression of lung cancer (Shiseki et al., 1994) .
Similar molecular changes seen in human lung cancer were also observed in mouse lung tumors as reviewed by Herzog et al. (1997) . The K-ras protooncogene is also frequently activated in both mouse lung adenomas and adenocarcinomas (Herzog et al., 1997) . LOH of chr.1, 4, 11, 12 and 14 were frequently detected in lung adenocarcinomas, suggesting that these changes may contribute to the progression of mouse lung carcinogenesis (Herzog et al., 1997) . However, the involvement of p53 alterations and LOH of K-ras wild type allele is relatively rare in mouse lung tumors (Herzog et al., 1997) . Recently, we have used a competitive cDNA library screening (CCLS) to examine gene expression in chemically induced lung adenocarcinomas from (C3H/HeJ6 A/J)F1 mice, and found that 14 genes were dierentially expressed in lung adenocarcinomas compared with normal lungs (Lin et al., 2001) .
The present study employed the Atlas Mouse aberrant expression is associated with lung tumor progression. We demonstrate that the expression of 19 genes is closely correlated with lung tumor progression and can be designated as candidate`lung tumor progression' genes. Our results provide clear evidence that expression of certain genes had been changed in the progression of mouse lung tumorigenesis from adenoma to adenocarcinoma.
Results
In this study, we used mouse lung adenomas, mouse lung adenocarcinomas and their paired normal lung tissues to examine the dierential expression of genes using the Atlas Mouse TM cDNA Microarray (Clontech Laboratories, Inc., Palo Alto, CA, USA). Representative examples of the pathological features of an adenoma and an adenocarcinoma and their paired normal alveoli are shown in Figure 1 . Lung adenoma is characterized by a monomorphic growth pattern and is generally comprised of well-dierentiated cells while lung adenocarcinoma is composed of cells with varying degrees of dierentiation. Additional features of lung adenocarcinoma include loss of normal alveolar architecture, increased nuclear/cytoplasmic ratio, nuclear crowding and cytologic atypia, heterogeneity of growth patterns, and invasion into adjacent bronchioles or vessels. The membrane contains cDNA fragments representing 588 known mouse genes. Each cDNA fragment is 200 ± 500 bp long and selected as a unique sequence with the following criterions: no poly-A tail; no repetitive elements; and no highly homologous sequences in order to minimize cross-hybridization and nonspeci®c binding of cDNA probe. These Figure 2 , approximately 152 genes were hybridized to probes from tumor or normal tissues, whereas the remaining 436 genes were not detected. Analysis showed that of the 152 genes, 108 were expressed at similar levels among normal tissues, adenomas and adenocarcinomas. The remaining 44 genes were expressed dierentially in at least three out of ®ve tumors, with 24 genes being overexpressed and 20 genes being underexpressed in tumors compared with paired normal tissues.
We further used semi-quantitative RT ± PCR analysis to con®rm dierential expression of the mRNAs in seven adenomas and seven adenocarcinomas in comparison with their paired normal tissues. To determine the linear range of each set of RT ± PCR reactions, a series of three to four PCR reactions using 18, 20, 22, or 24 cycles were performed for each target gene, and one of the reactions that ®t into the linear range was used for actual quantitation. Figure 3 shows the overexpressed and underexpressed genes, respectively. All positive results of RT ± PCR were repeated at least once to eliminate false positive data. Twenty of 44 genes were con®rmed by quantitative RT ± PCR. We also used gene-speci®c primers to perform quantitative RT ± PCR on several genes that did not show in cDNA microarray, nine genes were dierentially expressed (Tables 1 and 2 ). Ten genes showed dierential expression between normal tissues and tumors and were altered similarly in adenomas and adenocarcinomas (Table 1) . On average these genes displayed a 2 ± 4-fold increase or decrease in expression in tumors (adenomas or adenocarcinomas) as compared to normal lung tissue. The only exception was atrial fetal myosin which was highly expressed in normal lung but not at all expressed in tumors. Eight genes (c-Jun, FasL, YB-1, ADAP, CD31, CDC42, ACE and TRAIL) showed no change in adenomas, but were underexpressed in adenocarcinomas some by quite striking amounts. TRAIL was lost in all seven adenocarcinomas examined. Two genes, showed no change in adenocarcinomas, were altered in gene expression only in adenomas. Rab-2 was overexpressed, while Abi-1 was underexpressed in adenomas. Furthermore, Int-3 and B-raf were overexpressed in adenomas, but underexpressed in adenocarcinomas.
Seven genes (Stat1, BAG-1, BAX, VEGFR2, IGFBP-6, PDGF-A, and TGFb2) showed dierential expression in 67 ± 100% of the lung adenocarcinomas, but only 20 ± 57% in lung adenomas (Table 2) .
Discussion
Mouse lung tumor progression (from adenoma to adenocarcinoma) is the most important step of lung carcinogenesis since metastasis is extremely rare in mice. The results from the present study suggest that a group of genes are consistently and speci®cally altered during the progression stage of mouse lung tumor development. The changes in gene expression involved genes known to play a role in extracellular matrix adhesion disruption, cell cycle, apoptosis, and signal transduction. Speci®cally, 19 genes showed dierential expression/increased in incidence or displayed signi®-cant dierence in level of changes between lung adenomas and adenocarcinomas, including Stat1, ADAP, IGFBP-6, PDGF-A, TGF-b2, Int-3, VEGFR2, BAX, BAG-1, c-Jun, FasL, TRAIL, YB-1, CD31, Cdc42, B-raf, Rab-2, Abi-1, and ACE. We designated these genes as candidate`lung tumor progression' (LTP) genes because their expression changes may speci®cally aect lung tumor progression in mice. However, the mechanism(s) of their functional role in lung tumor progression is not known at present and additional studies will be required.
Some generalized ®ndings arise from this investigation are summarized here. First, looking at only 588 genes and employing limited amounts of total RNA, one can obtain signals from roughly one fourth of the identi®ed genes (152 out of 588). Furthermore, roughly one ®fth (29 out of 152) of those genes resulted in signi®cant changes in gene expression in lung adenomas or adenocarcinomas. If we had pooled samples and used poly(A) + RNA as contrasted with total RNA in the study, we were likely to have achieved signals from a greater number of the genes represented on the array. Another interesting aspect of the results is that 10 of the genes showed the same pattern in both adenomas and adenocarcinomas, speci®cally increases or decreases in both classes of lesions. A number of genes that showed minimal alterations in adenomas showed decreases in expression in adenocarcinomas (e.g. VEGFR2, TRAIL, TGF-b2). In contrast, only a single gene showed increased expression in adenocarcinomas while showing little if any changes in adenomas. Interestingly, there were genes which showed fairly consistent increases in expression in adenomas but showed consistent decreases in adenocarcinomas (Int-3, Fas antigen ligand, CD31 platelet cell adhesion molecule).
One of the major pathways that are routinely altered in most cancer types is the Rb pathway. The expression of ®ve genes (cyclin D1, cyclin B2, CDK4, p57 KIP2 and TGF-b2) aecting this pathway were altered with overexpression of cyclin D1, cyclin B2 and CDK4 and underexpression of p57 KIP2 and TGF-b2 in both ; (5) MAPKK1; (6) clusterin; (7) YB-1; (8) IGFBP-6; (9) TGF-b 2; and (10) fetal myosin alkali light chain Candidate mouse lung tumor progression genes R Yao et al mouse lung adenomas and adenocarcinomas when compared to normal lungs. In G1 phase, cyclin D1 associates with CDK4 and leads to the phosphorylation and inactivation of pRb that triggers the transition from G1 into S phase (Chellappan et al., 1991) . Cyclin B2 is involved in regulating the G2/M progression of the cell cycle (Ludlow et al., 1993) . p57 KIP2 , a member of the CIP/KIP family, is able to inhibit the activity of all CDKs and may act as a tumor suppressor (Sherr and Roberts, 1999) . TGF-b treatment induces growth arrest through the down-regulation of cell cycle regulators, including cyclin E, cyclin A, CDK2 and CDK4 (Geng and Weinberg, 1993) . TGF-b induces expression of CDK4/6 speci®c inhibitor p15 INK4B , p21 WAF1 and p27 Kip1 (Li et al., 1995; Reynisdottir et al., 1995; Kleef and Korc, 1998) . Our study indicated that overexpression of cyclin D1, cyclin B2, CDK4 and underexpression of p57 KIP2 and TGF-b may be involved in mouse lung tumorigenesis.
Activation of Raf, a direct eector of Ras, leads to activation of MEKs through MAP kinase pathway. The mouse lung adenomas and adenocarcinomas employed here routinely have mutations in the K-ras gene. Activated MEKs in turn phosphorylate dierent MAP kinases (ERKs). Translocation of activated MAP kinase to the nucleus results in transcriptional activation by either activating nuclear transcriptional factors, or activating other kinases that are critical for subsequent protein synthesis. We found ®ve genes (Braf, c-jun, MAPKK1, ATF4, and Stat1) that associated with this pathway showing dierential expression in lung tumors. B-raf, MAPKK1, and c-jun are three Figure 3 Semi-quantitative RT ± PCR analysis for genes dierentially expressed in mouse lung tumors. Lanes 1 to 2 are two controls from paired normal lung tissues. Lanes 3 to 7 and Lanes 8 to 13 are mouse lung adenomas and adenocarcinomas, respectively. In each panel, the top bands are the PCR fragments of a housekeeping gene, GAPDH, which have been co-ampli®ed in the same reaction tube with the gene of interest as internal control. N, A and AC: normal, adenoma, adenocarcinoma, respectively (Crews et al., 1992; Kyriakis et al., 1992) . We had expected that the expression of all three (B-raf, MAPKK1, and c-jun) would be increased in lung adenomas and/or lung adenocarcinomas. MAPKK1 was overexpressed in both adenomas and carcinomas tested. However, both B-raf and c-Jun were underexpressed in carcinomas in contrast to their expression in adenomas (B-raf was overexpressed in adenomas while the expression of c-jun was not altered in adenomas). It is not clear at present how downregulation of B-raf and c-Jun may contribute to the progression of lung adenomas to adenocarcinomas. It was also shown that ATF4 was underexpressed in both mouse lung adenomas and adenocarcinomas. Recent studies have demonstrated that ATF4 (Activating transcription factor-4) is essential for normal cell cycling by regulating cyclin A expression (Shimizu et al., 1998) , and cell transformation through human c-Hras (Mielnicki et al., 1996) . Dimerization of ATF4 with Jun or Fos family members alters the Jun/Fos DNA binding site from an AP-1 site to a CRE site that regulates gene transcription (Hai and Curran, 1991) . Inappropriate activation of the Stat genes has been found in human malignancies (Frank, 1999) . Stat1 was overexpressed 2 ± 5-fold in four out of ®ve adenomas and 4 ± 13-fold in four out of six adenocarcinomas suggesting that expression of Stat1 is associated with lung tumor progression. Expression of Int-3, a truncated form of Notch4 having most of its extracellular domain deleted, as a transgene in mice induces the formation of poorly dierentiated mammary carcinomas (Imatani and Callahan, 2000) . However, overexpression of active forms of Notch1 and Notch2 can cause a profound growth arrest in DMS53 and NCI-H209 SCLC cells through up-regulation of p21 waf1/cip1 and p27 kip1 , suggesting that the previously described function of Notch proteins as proto-oncogenes is highly contextdependent (Sriuranpong et al., 2001) . In concordance with this study, our study showed that int-3 was slightly overexpressed (2 ± 4-folds) in all mouse lung adenomas (5 out of 5) but signi®cantly underexpressed (8 ± 16-folds) in all mouse lung adenocarcinomas (6 out of 6). These data indicate that Int-3 may play an important role in mouse lung tumor progression through its function on cell cycle.
Four apoptosis related genes were found dierentially expressed in mouse adenomas and adenocarcinomas. BAG-1 and Bax were underexpressed in 40% (2 out of 5) lung adenomas, but more frequently in 85% (6 out of 7), and 100% (7 out of 7) lung adenocarcinomas, respectively. Fas ligand and TRAIL did not exhibit any changes in mouse lung adenomas, but were signi®cantly decreased (FasL) or completely lost (TRAIL) in all lung adenocarcinomas. BAG-1 is an antiapoptotic protein that binds to and enhances the antiapoptotic activity of Bcl-2. The decrease in Bax expression in adenocarcinomas is more signi®cant since it is expected to promote apoptosis through heterodimerization with two potent antiapoptotic genes Bcl- (Oltvai et al., 1993) . High levels of BAG-1 and Bcl-2 are associated with lung cancers (Yang et al., 1998) . In highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line, FasL was downregulated (Gemma et al., 2001) . In patients with non-small-cell lung carcinomas, the median survival times of cancer patients with FasL expression was 87 weeks and of those without FasL expression only 41 weeks (Volm and Koomagi, 2000) . Together with previous ®ndings, these results indicate that malfunction of cell apoptosis is a potential mechanism for the lung tumor progression.
Our study indicated that IGFBP-6 was downregulated in both mouse lung adenomas (3 out of 5, sixfold) and adenocarcinomas (6 out of 6, 10 ± 20-folds). Although the function of IGFBP-6 is still obscure, our study suggests that IGFBP-6 may be involved in mouse lung tumor progression due to its induction of apoptosis and its regulation of IGF. Recent ®ndings indicate that IGFBP-6 is a potent inducer of programmed cell death in cancer cells (Sueoka et al., 2000) . One study showed that infection of NSCLC cell lines in vitro with an adenovirus expressing human IGFBP-6 under the control of a CMV promoter (Ad5CMV-BP6) reduced NSCLC cell number through activation of programmed cell death. The growth regulatory eect of IGFBP-6 was investigated in vivo by intratumoral injection of Ad5CMV-BP6 in NSCLC xenografts established in nu/nu mice. A single injection of Ad5CMV-BP6 reduced the size of NSCLC xenografts by 45% (Sueoka et al., 2000) .
Several genes involving angiogenesis, cellular structure, and other cellular functions were also aected during mouse lung tumorigenesis and progression. KDR/Flk-1 was underexpressed particularly in lung adenocarcinomas. This ®nding is somewhat surprising and needs further examinations because KDR/Flk-1 is one of the receptors for VEGF mediating angiogenic signals. Rab2, a member of the Rab small GTPase family, localizes to pre-Golgi intermediates and participates in membrane trac in the early secretive pathway (Tisdale and Jackson, 1998). CDC42, a member of Rho small GTPase family, participates in the organization of actin cytoskeleton, gene transcription, cell cycle progression, and membrane tracking (Kjùller and Hall, 1999) . CD44-hyaluronan mediated cell adhesion is important in in¯ammation and cancer cell metastases (Sneath and Mangham, 1998) . These genes were also found dierentially expressed in mouse lung tumors in this study suggesting that these genes may play a role in mouse lung tumorigenesis by disrupting cell adhesion, internal cytoskeleton structure and membrane tracking. Additional altered genes include abiphilin-1 (Abi-1), adipocyte dierentiation-associated protein, CD31, angiotensin-converting enzyme (ACE), RNA polymerase 1 termination factor (TTF-1), YB-1 DNA binding protein, PKC-d, and myosin alkali light chain genes. As mentioned earlier, further investigation should be carried out for a better understanding of these genes in mouse lung tumorigenesis.
Finally, this study indicates that Atlas Mouse TM cDNA expression array analysis can be a useful technique to identify dierentially expressed genes in mouse lung tumors. The Atlas cDNA expression array is used extensively to study changes in gene expression in dierent systems (DeRisi et al., 1996; Rhee et al., 1998) . There are at least two major advantages of the Atlas cDNA expression array over other types of cDNA microarray approaches. First, it contains known genes related to`oncogenesis' that most likely will signi®cantly increase the possibility of their detection because of their association with the carcinogenic process. Thus, the frequency of dierential expression will unlikely be the same when a more global analysis of gene expression is undertaken. Second, it can accommodate the use of a very small amount of tissues. The adenomas employed in this model are quite small, perhaps yielding as few as 0.5 ± 2 micrograms of total RNA. Such an approach is also more likely to prove useful in examining small biopsy samples from the clinic.
Materials and methods

Lung tumors
At six-weeks of age, 10 female A/J mice were divided into two groups and received a single i.p. injection of Nmethylnitrosourea (MNU) in acidi®ed saline (pH 5.0) at a dose of 50 mg/kg body weight. The ®rst group of mice was terminated at 6 months of age and the second group of mice was terminated at 14 months of age. The tumors were harvested and frozen in liquid nitrogen until RNA analysis. All frozen tumor tissues were microdissected to determine the tumor vs normal cell ratio for each specimen. Tissues were embedded in Tissue Tek OCT compound (VWR Scienti®c Products, West Chester, PA, USA), cryostat sectioned, and stained with hemotoxin and eosin for microscopy. Tumor tissue sections corresponding to the microscopic sections containing 580% tumor cells were isolated and stored at 7808C for subsequent RNA isolation. Matching normal tissues were also microdissected to ensure that specimens consisted of purely normal lung tissue. Figure 1 shows the typical morphology of normal alveoli, an adenoma, and an adenocarcinoma used in this study.
RNA isolation
Total RNA from lung adenomas and lung adenocarcinomas and their paired normal lung tissue was isolated using TRI reagent (Molecular Research Center, Cincinnati, OH, USA). The tissue was frozen in liquid nitrogen and pulverized, then homogenized in 1 ml of TRI reagent, incubated for 5 min at room temperature, followed by addition of 200 ml chloroform, vigorous mixing, and incubation on ice for 15 min. The sample was centrifuged at 14 000 r.p.m. for 20 min; the aqueous phase was transferred to a fresh tube with an equal volume of isopropanol, and incubated on ice for 30 min. After centrifugation at 14 000 r.p.m. for 15 min, the RNA pellet was washed in 75% ethanol and dissolved in RNasefree water. The quality of RNA was con®rmed on a formaldehyde agrose gel, and the concentration was determined by reading absorbance at 260/280 nm.
Labeling cDNA probes by reverse transcription (RT) 32 P-labeled cDNAs were prepared from 2 mg of total RNA using 100 mCi [a-32 P]-dCTP. Brie¯y, a mixture containing a 2 mg sample total RNA and 2 ml oligo dT primer (Promega, Madison, WI, USA) was incubated at 658C for 10 minutes, then chilled on ice. The 25 ml reaction mixture, containing 16reverse transcription buer (50 mM Tris-HCl, pH 8.3; 75 mM KCl; 3 mM MgCl 2 ; 10 mM DTT; 0.2 mg/ml BSA); 2.5 mM of dTTP, dATP, dGTP, and 100 mCi [a-
32 P]-dCTP; 100 units RNasin (Promega, Madison, WI, USA); and 200 units of M-MLV reverse transcriptase (GIBCO-BRL, Life Technology Co., Gaithersburg, MD, USA), were incubated at 378C for 1 h. Then the reverse transcribed sample was applied to the center of the gel bed in a Sephadex G-50 Column (Boehringer Mannheim, IN, USA). After centrifugation at 2500 r.p.m., the probe was collected and the labeling activity was determined by Beckman LS 3801 Liquid Scintillation Counter. Before hybridization, 5 ml of mouse Cot-I DNA was added and denatured at 958C for 10 min.
cDNA microarray hybridization
Gene expression was analysed using the Atlas Mouse cDNA Expression Array (Clontech Laboratories, Inc., Palo Alto, CA, USA). Five sets of arrays were done for adenomas vs normal tissues and adenocarcinomas vs normal tissues. After 12 h of prehybridization in 10 ml of hybridization solution at 428C in a roller bottle, equal amounts of 32 P-labeled cDNA from tumor and paired normal tissue were then hybridized to two Atlas Mouse cDNA Expression Arrays. Hybridization solution was composed of the following: 50% formamide, 56SSPE, 56Denhardt's solution, 0.1% SDS and 100 mg/ml of denatured herring sperm DNA. The hybridization was performed at 428C for 18 h with mild rolling or shaking. Membranes were stringently washed with agitation for 10 min in 26SSC/0.1% SDS twice at room temperature and then for 30 min in 0.16SSC/0.1% SDS twice at 658C.
PhosphorImaging analysis and quantitation of gene expression
Membranes were exposed to a Phosphor Screen for 5 ± 8 h and scanned using a Storm 840 PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA, USA). Autoradiographic intensity was analysed using ImageQuant software (version 1.1, Molecular Dynamics). The expression level for each gene was quanti®ed after background correction.
Quantitative RT ± PCR analysis
Two mg of total RNA was converted into ®rst strand cDNA in a total reaction volume of 50 ml using oligo(dT) 15 ± 18 primer. Brie¯y, after incubating the RNA at 658C with 2 ml oligo(dT) 15 ± 18 for 10 min and chilling on ice for 5 min, the following components were added: 10 ml of 56reaction buer (250 mM Tris-HCl, pH 8.3; 375 mM KCl, 15 mM MgCl 2 ), 10 mM DTT, 2.5 mM each of dNTP, 100 units RNasin and 200 units M-MLV reverse transcriptase. The reaction mixture was incubated at 378C for 1 h followed by inactivation of enzyme at 958C for 5 min. A 2 ml aliquot of the resulting 50 ml cDNA mixture was used to perform a quantitative RT ± PCR analysis. Quantitative RT ± PCR was performed under the following conditions: 18 to 24 ampli®cation cycles of 948C for 1 min, 558C for 1 min, and 728C for 1 min in 0.2 mM dNTPs, 1.5 mM MgCl 2 , 1 mM downstream clone-speci®c primer, 1 mM [g-32 P]-ATP endlabeled upstream clone-speci®c primer, and 0.025 unit Taq DNA Polymerase (Promega). GAPDH was co-ampli®ed as an internal control. The forward primer of GAPDH was also end-labeled with [g-32 P]-ATP using T4 polynucleotide kinase. To determine the linear range of each PCR reactions, a series of three to four PCR reactions using 18, 20, 22, or 24 cycles were performed each target gene, and one of the reactions ®ts into the linear range was used for further quantitation. The PCR products were resolved in an 8% denaturing polyacrylamide gel. After exposure of the gel to a PhosphorImage Screen for 3 ± 5 h, the screen was scanned and analysed as previously described.
Statistical analysis
After normalization to the level of GAPDH cDNA ampli®cation in the multiplex PCR reactions using cDNAs from both normal lungs and lung adenomas or lung adenocarcinomas, Student's t-test was used to determine the dierence in the signal intensity of phosphor imaging between normal lungs and lung adenomas or lung adenocarcinomas.
